tag:blogger.com,1999:blog-22694944417840027782024-03-13T10:52:50.498-07:0012th International Conference on Pharmacoepidemiology and Clinical Research<b>Theme:</b> Broaden the possibilities for Policy, Education, and Advocacy in the field of Pharmacoepidemiology and Clinical Research<br>
<b>Date:</b> March 18-19, 2019 <br>
<b>Conference Venue:</b> Dubai, UAE
Asia Pacific Conferencehttp://www.blogger.com/profile/10138955357050690328noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-2269494441784002778.post-30566097086260069712018-10-14T23:27:00.004-07:002018-10-14T23:27:46.374-07:00Current pharmacologic management strategies in aneurysmal subarachnoid hemorrhage<div dir="ltr" style="text-align: left;" trbidi="on">
<br />
<div style="background: white; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 6.0pt;">
<b><span style="color: black; mso-themecolor: text1;">Subarachnoid
hemorrhage</span></b><span style="color: black; mso-themecolor: text1;"> (<b>SAH</b>)
is bleeding into the subarachnoid space the zone between the arachnoid layer
and the pia mater encompassing the brain. Symptoms may incorporate a serious
rapid headache, diminished level of consciousness, vomiting, fever, and in some
cases seizures. Neck solidness or neck pain are also relatively common. In
about a fourth of individuals a small bleed with resolving symptoms occurs
within a month of a larger bleed. <o:p></o:p></span></div>
<div class="MsoNormal">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;">SAH may happen
because of head injury or unexpectedly, as a rule from a ruptured cerebral
aneurysm. Risk factors for unconstrained cases included hypertension, smoking,
family history, and liquor addiction. For the most part, the determination can
be controlled by a CT scan of the head if done inside six hours. Occasionally a
lumbar cut is also required. After affirmation additionally tests are generally
performed to decide the basic reason. <o:p></o:p></span></div>
<div style="background: white; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 6.0pt;">
<span style="color: black; mso-themecolor: text1;">Treatment
is by prompt neurosurgery or radiologically guided mediations. Medications, for
example, labetalol might be required to bring down the pulse until the point
that repair can happen. Efforts to treat fevers are also recommended.
Nimodipine, a calcium channel blocker, is oftentimes used to anticipate
vasospasm. Routine utilize medications to avert encourage seizures is of unclear
benefit. Almost 50% of individuals with a SAH because of an underlying aneurysm
die within 30 days and about a third who survive have ongoing issues. 10– 15
percent die before reaching a hospital. <o:p></o:p></span></div>
<div class="MsoNormal">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;">Aneurysmal
subarachnoid hemorrhage (aSAH) is a particularly devastating neurologic insult
as the majority of </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/patient-safety-and-adverse-drug-reactions"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">patients
suffer</span></a><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;"> mortality and morbidity
at the time of rupture, and from subsequent complications. At least one-third
of patients die shortly after experiencing a ruptured cerebral aneurysm, and
around 60% of survivors develop debilitating neurologic deficits throughout
their course of treatment. In many cases, spastic narrowing of large cerebral
vessels, termed cerebral vasospasm, has been associated with delayed cerebral
ischemia (DCI) and stroke 4 to 21 days post-hemorrhage. Despite decades of
numerous </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/clinical-data-management"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">clinical
trials</span></a><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;"> and animal
research, highly effective pharmacological treatment options for aSAH patients
are lacking. <o:p></o:p></span></div>
<div class="MsoNormal">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi2dhk5_8_vPQy64llbL0i1pEyMqiq6jpulL2a3O6nyS7XrcnFttxbAGtvTS08WeLRQeEmF0a98sQGnJsf7TErY3YRBUGDhK5_fKofLZYMNj9sfTegMrGQe-aLFnNKOfW-wfDzzaREs7ZY/s1600/subarachnoidhemorrhagessjg3_blog+pic.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="212" data-original-width="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi2dhk5_8_vPQy64llbL0i1pEyMqiq6jpulL2a3O6nyS7XrcnFttxbAGtvTS08WeLRQeEmF0a98sQGnJsf7TErY3YRBUGDhK5_fKofLZYMNj9sfTegMrGQe-aLFnNKOfW-wfDzzaREs7ZY/s1600/subarachnoidhemorrhagessjg3_blog+pic.jpg" /></a></div>
<div class="MsoNormal">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;"><br /></span></div>
<div class="MsoNormal">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;"><b style="mso-bidi-font-weight: normal;">Pharmacological Management Strategies:<o:p></o:p></b></span></div>
<div class="MsoNormal">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;">The cerebral
vasospasm, is assessed radiographically, or clinically is not the appropriate
target for </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/drug-discovery-and-drug-screening"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">drug
development</span></a><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;">. It’s
presence in aSAH patients is not consistently associated with cerebral
infarctions leading to poor outcomes, and many patients in whom cerebral
vasospasm is mild or absent nonetheless suffer long-term disabilities and
mortality. Pharmacological therapies that effectively attenuate cerebral
vasospasm do not significantly improve long term outcomes, perhaps best exemplified
in clinical trials using Eta receptor antagonists. Nimodipine, the only </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/molecular-pharmacoepidemiology"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">pharmacologic
therapy</span></a><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-themecolor: text1;"> to improve aSAH,
does not reliably attenuate cerebral vasospasm. It is evident that more
comprehensive understanding of the injury process is needed, into further
developing strategies for thrombosis and vasospasm in the microvasculature,
spreading cortical depolarization and early brain injury. Efforts to eliminate
ambiguities in the use of terms and procedures to assess delayed cerebral
ischemia should also enhance progress in this field.<o:p></o:p></span></div>
<br /></div>
Anonymoushttp://www.blogger.com/profile/05676993119021367292noreply@blogger.com0tag:blogger.com,1999:blog-2269494441784002778.post-68036968186426267912018-10-11T21:56:00.001-07:002018-10-11T21:56:04.694-07:00Risk of cardiovascular complications in hypertensive smokers and antihypertensive treatment: Metanalysis of small-case reports<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal">
<span style="background: white; font-family: "Times New Roman", serif; font-size: 12pt; line-height: 115%;">Smoking is a risk issue for mortality and coronary
cardiovascular disease in high blood pressure and in diabetes. The chance for
stroke is a smaller amount consistent in high blood pressure and appears to be
smaller than that of CHD in diabetes. High blood pressure is a powerful
independent contributor to cardiovascular morbidity and mortality, on the
average conferring a threefold increase in risk at all ages and in each sex.
Coronary cardiovascular disease is currently the chief lethal abnormal
condition of high blood pressure, occurring at a rate 2 to 3 times higher in
hypertensives than in normotensives. The risk of cardiovascular morbidity and
mortality is additionally greatly affected by cigarette smoking. For every ten
cigarettes per day there's an progressive increase in cardiovascular mortality
in men (18%) and in women (31%).<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="background: white; font-family: "Times New Roman", serif; font-size: 12pt; line-height: 115%;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTOfjMzB9YoRzrma0HRqe0oPvTvMSo9_cNJkBtcLvadTm4qwqVQOA_ebi70HJ4rNvQBYLHVLvKDa3PAmH9OXT260lkQVsUbcTEXH3NUCp7gy1DZZMXTheKOZabV7D5Fb1HyYjNZ4SVY10/s1600/cardiovascular+risks+in+smokers.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="708" data-original-width="1200" height="188" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTOfjMzB9YoRzrma0HRqe0oPvTvMSo9_cNJkBtcLvadTm4qwqVQOA_ebi70HJ4rNvQBYLHVLvKDa3PAmH9OXT260lkQVsUbcTEXH3NUCp7gy1DZZMXTheKOZabV7D5Fb1HyYjNZ4SVY10/s320/cardiovascular+risks+in+smokers.jpg" width="320" /></a></div>
<div class="MsoNormal">
<span style="background: white; font-family: "Times New Roman", serif; font-size: 12pt; line-height: 115%;"><br /></span></div>
<div class="MsoNormal">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Antihypertensive
drug<o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/drug-discovery-and-drug-screening"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Antihypertensives
drugs</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> are a class of drugs that are used to treat
hypertension. Antihypertensive therapy is to prevent the complications of high
blood pressure (HighBP), such as myocardial infarction and stroke. Evidence
suggests that the risk of stroke can be decrease to 34% by reduction of the
blood pressure by 5 mmHg, of ischaemic heart disease by 21%, and reduce the
heart failure, likelihood of dementia and mortality from </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/cardiovascular-pharmacology"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">cardiovascular
disease</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">. There are many classes of antihypertensive, which
lower blood pressure by different means. Among the most important and most
widely used drugs are calcium channel blockers, thiazide diuretics, angiotensin
II receptor antagonists, ACE inhibitors, and beta blockers.<o:p></o:p></span></div>
<div class="MsoNormal">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Metanalysis:
<o:p></o:p></span></b></div>
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;">Metanalysis of
large-scale trials showed combined action of hypertension (H) and smoking (S)
as a potent risk factor for cardiovascular disease and both deaths and
non-fatal events .The metanalysis of small-case reports of hypertensive smokers
(Blood Pressure-BP- >140/90 mmHg) analyzing the incidence and type of
cardiovascular complications results
observed indicated that a higher incidence of cardiac and cerebrovascular
events affected hypertensive exposed chronically, current smokers, with a
statistical significance, while smokers acutely exposed showed transient but
stable increase in heart rate and systolic BP in all studied subjects. The type
of </span><span style="font-family: "Calibri","sans-serif"; font-size: 11.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-ascii-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-bidi-language: AR-SA; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin;"><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/clinical-pharmacology-and-therapeutics"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">pharmacological
treatment</span></a></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"> does not influence the metanalysis results.
Acute exposure to smoking increased heart rate and BP, while chronic exposure
showed a significantly greater number of cardiovascular complications for S+H
similarly to what observed in metanalysis of large-scale trials. <br />
<!--[if !supportLineBreakNewLine]--><br />
<!--[endif]--></span></div>
Anonymoushttp://www.blogger.com/profile/05676993119021367292noreply@blogger.com0tag:blogger.com,1999:blog-2269494441784002778.post-72002240850231123352018-09-28T22:14:00.002-07:002018-09-28T22:14:25.658-07:00New Antibody Conjugates in Cancer Therapy<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Targeting of drugs,
radiation and protein toxins to cancer selectively with monoclonal antibodies
(MAbs) has been considerable as a topic of interest and an area of continued
development. </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/immunopharmacology"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Radioimmunotherapy</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">
of lymphoma using directly labeled MAbs is of current interest after approval
of two radiolabeled anti-CD20 MAbs, as illustrated with the near 100% overall
response rate obtained in a recent clinical trial using an investigational
radiolabeled 90Y-epratuzumab ,anti-CD22 MAb. The advantage of pre targeted RAIT
over directly labeled MAbs is continuing to be validated in preclinical models
of solid tumors and lymphoma. Importantly, the advantages of combining RAIT
with radiation sensitizers, with immunotherapy, or a drug conjugate targeting a
different antigen are being studied clinically and pre clinically. The area of </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/drug-discovery-and-drug-screening"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">drug-conjugated
antibodies</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> is progressing with encouraging data for the
trastuzumab-DM1 conjugate in a phase I clinical trial in HER2-positive breast
cancer. The technology of Dock-and-Lock platform has contributed to the design
and the evaluation of antibody-toxin conjugates and complex antibody-cytokine. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg_njyOjTTzkHDgeIiErgTgIv7_IPeCI1EhmwGybPUR7hotAeiaYRiZg_b-UfrUkGn8ASVcD3JNe7zpQLOA1qV7598fVnMX7sev8gJR4-AGtjAcSnBhbWqQPANaQYpSdpQgK-8UQQvK-oc/s1600/drug_conjugate.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="195" data-original-width="582" height="107" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg_njyOjTTzkHDgeIiErgTgIv7_IPeCI1EhmwGybPUR7hotAeiaYRiZg_b-UfrUkGn8ASVcD3JNe7zpQLOA1qV7598fVnMX7sev8gJR4-AGtjAcSnBhbWqQPANaQYpSdpQgK-8UQQvK-oc/s320/drug_conjugate.jpg" width="320" /></a></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b style="mso-bidi-font-weight: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">RADIOIMMUNOCONJUGATES
<o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Radioimmunotherapy
(RAIT) involves in the application of radiolabeled MAbs for targeted
radiotherapy (RT). Both directly radiolabeled MAbs and in vivo radiolabelings
of tumor-targeted MAbs by complexation with radiolabeled haptens have been
developed.<span style="mso-spacerun: yes;"> </span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b style="mso-bidi-font-weight: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Radionuclides
Used for RAIT <o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Tumoricidal effects
produced by continuous low-dose irradiation from a tumor-targeted radiolabeled
MAb. For therapy, α- and β-particle emitters are of practical relevance. There
have been numerous investigations with a number of these radionuclides, but for
use with whole antibodies, the most promising radionuclides are the β-emitters
131I, 90Y, and 177Lu. 90Y is a max-energy β-emitter (Emax: 2,280 keV; max
range: 12 mm) with a 64-h half-life, while 131I has a higher half-life of 8.1
days with low-intermediate energy (610 keV, range: 2.0 mm). 131I is quickly
removed from tumor cells after </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/antibiotic-pharmacology"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">intracellular
antibody</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> catabolism so it is not suitable for use with internalizing
MAbs. The forms of intracellularly trapped 131I have been designed by us and
others for use with internalizing MAbs. A recent study of IMP-R4 template utilized
for incorporating residualizing radioiodine for immuno-PET quantitation of
de2-7 EGFR expression in glioma in a xenograft model using 124I-IMP-R4–labeled
anti-EGFR antibody, ch806. Residualizing use of radioiodine method for clinical
RAIT may be supplanted by the availability of the metallic radionuclide 177Lu,
which has radiophysical properties similar to those of 131I and radiolabeling
chemistry similar to that of 90Y. <o:p></o:p></span></div>
</div>
Anonymoushttp://www.blogger.com/profile/05676993119021367292noreply@blogger.com0tag:blogger.com,1999:blog-2269494441784002778.post-75963527313196421922018-09-21T22:21:00.003-07:002018-09-21T22:21:36.431-07:00Current status of recombinant antibodies in cancer therapy<div dir="ltr" style="text-align: left;" trbidi="on">
<br />
<div class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 18.75pt; mso-outline-level: 1;">
<span style="font-family: "Times New Roman", serif; font-size: 12pt; text-align: justify;">There are
many types of cancer treatment. The types of treatment that you receive will
depend on the type of cancer you have and how advanced it is. Some people with
cancer will have only one treatment. But most people have a combination of
treatments, such as surgery with chemotherapy and/or radiation therapy, hormone
therapy, targeted therapy, immunotherapy and<span style="color: #2e2e2e;"> </span></span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/personalized-precision-medicine" style="text-align: justify;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;">precision medicine</span></a><span style="color: #2e2e2e; font-family: "Times New Roman", serif; font-size: 12pt; text-align: justify;">.</span></div>
<div class="MsoNormal" style="background: white; text-align: justify;">
<a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/antibiotic-pharmacology"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Antibodies</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">
have come a long way from those <span style="mso-bidi-font-weight: bold;">initial</span> isolated by hybridoma over <span style="mso-bidi-font-weight: bold;">thirty</span> years <span style="mso-bidi-font-weight: bold;">past</span> to <span style="mso-bidi-font-weight: bold;">trendy</span> engineered fragments, <span style="mso-bidi-font-weight: bold;">made</span> by rational <span style="mso-bidi-font-weight: bold;">design</span>. <span style="mso-bidi-font-weight: bold;">The utilization</span> of antibodies in </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/cancer-pharmacoepidemiology-and-genomics"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">cancer <span style="mso-bidi-font-weight: bold;">therapy</span> </span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">is
increasing <span style="mso-bidi-font-weight: bold;">apace</span>,
with <span style="mso-bidi-font-weight: bold;">eleven</span> antibodies
approved over the past decade and <span style="mso-bidi-font-weight: bold;">quite</span> <span style="mso-bidi-font-weight: bold;">five hundred</span> <span style="mso-bidi-font-weight: bold;">in progress</span> clinical trials
involving monoclonal antibodies. <span style="mso-bidi-font-weight: bold;">The mixture</span> of the antibody's inherent characteristics with
the growing pool of tumour-specific antigens has generated <span style="mso-bidi-font-weight: bold;">a large</span> array of antibody-derived
tools that <span style="mso-bidi-font-weight: bold;">area unit</span> specifically
designed to suppress and eliminate cancer cells. <o:p></o:p></span></div>
<div class="MsoNormal" style="background: white; text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi99rMI-2es1XKH-aN_3GxUdo2fDGXvqQRumZ8YPkNqeJSGxO9ckfw6MDGV3mfh49vpb9ilLobpDiixf7c2J2EET-JeNkn4aEXrxAWGU9CiVVHI-Up4hrwDDeEbY3lyvhovtrPOaIPUrI0/s1600/Blog+image..jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="450" data-original-width="600" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi99rMI-2es1XKH-aN_3GxUdo2fDGXvqQRumZ8YPkNqeJSGxO9ckfw6MDGV3mfh49vpb9ilLobpDiixf7c2J2EET-JeNkn4aEXrxAWGU9CiVVHI-Up4hrwDDeEbY3lyvhovtrPOaIPUrI0/s320/Blog+image..jpg" width="320" /></a></div>
<div class="MsoNormal" style="background: white; text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="background: white; text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Recombinant antibodies have evolved into successful therapeutics with <span style="mso-bidi-font-weight: bold;">ten</span> approved for cancer and <span style="mso-bidi-font-weight: bold;">additional</span> <span style="mso-bidi-font-weight: bold;">within the</span> pipeline. Four
of <span style="mso-bidi-font-weight: bold;">the highest</span> <span style="mso-bidi-font-weight: bold;">10</span> cancer <span style="mso-bidi-font-weight: bold;">therapy</span> <span style="mso-bidi-font-weight: bold;">medicine</span>s are recombinant antibodies. Objectives: To survey <span style="mso-bidi-font-weight: bold;">the present</span> <span style="mso-bidi-font-weight: bold;">progressive</span> <span style="mso-bidi-font-weight: bold;">lightness</span> <span style="mso-bidi-font-weight: bold;">the explanations</span> for this success <span style="mso-bidi-font-weight: bold;">and looking out</span> ahead to <span style="mso-bidi-font-weight: bold;">subsequent</span> generation of antibody
therapy. Methods: <span style="mso-bidi-font-weight: bold;">AN</span> analysis
was <span style="mso-bidi-font-weight: bold;">dispensed</span> <span style="mso-bidi-font-weight: bold;">to spot</span> preclinical and </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/clinical-pharmacology-and-therapeutics"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">clinical</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">
examples <span style="mso-bidi-font-weight: bold;">and also the</span> underlying <span style="mso-bidi-font-weight: bold;">ideas</span> and mechanisms that have
shown <span style="mso-bidi-font-weight: bold;">a way to</span> <span style="mso-bidi-font-weight: bold;">design</span> <span style="mso-bidi-font-weight: bold;">higher</span> therapies. Results<b> </b>greater understanding
of the molecular basis of cancer has <span style="mso-bidi-font-weight: bold;">led</span> to improved antibodies and a greater<b> </b><span style="mso-bidi-font-weight: bold;">choice</span> of targets. Fine <span style="mso-bidi-font-weight: bold;">standardisation</span> of <span style="mso-bidi-font-weight: bold;">successful</span> antibodies through
modification of glycosylation, affinity, size and <span style="mso-bidi-font-weight: bold;">different</span> parameters <span style="mso-bidi-font-weight: bold;">area unit</span> paying dividends. Fc-engineering <span style="mso-bidi-font-weight: bold;">is probably going</span> to be
predominant <span style="mso-bidi-font-weight: bold;">within the</span> <span style="mso-bidi-font-weight: bold;">close<b> </b>to</span> future <span style="mso-bidi-font-weight: bold;">however</span> conjugates, fragments and
fusion proteins <span style="mso-bidi-font-weight: bold;">can</span> <span style="mso-bidi-font-weight: bold;">still</span> be developed and <span style="mso-bidi-font-weight: bold;">find<b> </b></span>their place <span style="mso-bidi-font-weight: bold;">within the</span> arsenal of antibody
therapeutics.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; vertical-align: baseline;">
<br /></div>
<div class="MsoNormal">
<br /></div>
<br /></div>
Anonymoushttp://www.blogger.com/profile/05676993119021367292noreply@blogger.com0tag:blogger.com,1999:blog-2269494441784002778.post-436148945802272112018-08-25T02:28:00.002-07:002018-08-25T02:28:38.884-07:00How to dose cytotoxic chemotherapeutic drugs<div dir="ltr" style="text-align: left;" trbidi="on">
<br />
<h1 style="background: white; margin-top: 0cm;">
<span style="color: black; font-size: 14.0pt; mso-themecolor: text1;">Cytotoxic drugs or cytostatics<o:p></o:p></span></h1>
<div class="lead" style="background: white; text-align: justify;">
Cytotoxic medications
or cytostatics are drugs used to pulverize tumor cells. Cytotoxic drugs inhibit
cell division and in this way cause cancer cells to die. Cytotoxic medications
are transported in the circulatory system all through the body. Cytotoxic medications
can be utilized to crush tumors, help the results of medical procedure or
radiotherapy, decrease metastases and reduce malignancy indications. <span style="color: black; mso-themecolor: text1;">Cytostatics can destroy small tumours
that have not been detected in tests. </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/drug-discovery-and-drug-screening"><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-theme-font: major-fareast;">Cytotoxic
drugs</span></a> affect all healthy tissue, including those of dividing cells.
But since disease cells regularly isolate notably quicker than ordinary cells,
they are especially delicate to cytostatics. The consequences for ordinary
cells are less <span style="color: black; mso-themecolor: text1;">pronounced and
healthy cells also recover faster.<o:p></o:p></span></div>
<div class="lead" style="background: white; text-align: justify;">
<span style="color: black; mso-themecolor: text1;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZf1JjClpAjWFyr0of2HzwPqlnoDl7EwCf0apSpWr15X_nW77UD7X2uLtjQYDikK3cVeHiqfij21RPjpNKsZSIrPCspZkn8-FjO4L-YSOx64YBwM8MW4MYXgzuuwkU9iZSupLer21-jOs/s1600/chemotherapy-for-all-type-of-cancers-which-includes-the-latest-chemotherapeutic-modalities.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="440" data-original-width="440" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZf1JjClpAjWFyr0of2HzwPqlnoDl7EwCf0apSpWr15X_nW77UD7X2uLtjQYDikK3cVeHiqfij21RPjpNKsZSIrPCspZkn8-FjO4L-YSOx64YBwM8MW4MYXgzuuwkU9iZSupLer21-jOs/s320/chemotherapy-for-all-type-of-cancers-which-includes-the-latest-chemotherapeutic-modalities.jpg" width="320" /></a></div>
<div class="lead" style="background: white; text-align: justify;">
<br /></div>
<div class="lead" style="background: white; text-align: justify;">
Cytotoxic
chemotherapeutic specialists have vast individual fluctuation and narrow
therapeutic windows in pharmacokinetics/pharmacodynamics, dosing of these
operators requires exact change. In spite of the fact that the body-surface area
(BSA) has for quite some time been utilized for this reason, its adequacy for
limiting interpatient fluctuation in <a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/pharmacokinetics-and-pharmacodynamics">pharmacokinetics</a>
has been addressed. The components that conceivably add to between singular
changeability in medicate reaction are looked into, with an extraordinary
spotlight on cytotoxic chemotherapeutic medications, for example,
platinum-containing operators, taxanes, irinotecan, and antimetabolites. That the
utilization of BSA neglects to limit between tolerant inconstancies in sedate
reaction, causes bother in reconstituting singular dosages, and can result in
human mistake, introductory level dosing with consequent restorative medication
checking may be a sensible alternative.</div>
<h2 style="background: white; margin-top: 0cm;">
<span style="color: black; font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 115%; mso-themecolor: text1;">Side effects of cytotoxic drugs<o:p></o:p></span></h2>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Cytotoxic medications achieve
all cells in the body and they kill healthy cells as well as cancer cells. This
is the reason chemotherapy has antagonistic symptoms. Treatment as a rule
causes sickness, male pattern baldness and exhaustion. The reactions change
starting with one individual then onto the next. A portion of the reactions
vanish following a couple of days, however it for the most part takes a couple
of months for you to make a general recuperation from </span><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/cancer-pharmacoepidemiology-and-genomics"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">chemotherapy</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">.
Since cytostatics influence separating cells, a considerable lot of the
reactions are focused on inexhaustible tissue, for example, hair, bone marrow
and mucous layers. The sort and seriousness of the symptoms rely upon the
medications utilized, measurements, your general condition and how our body
reacts to the medications. The most well-known reactions would nowadays be able
to be viably averted and treated.<o:p></o:p></span></div>
<br /></div>
Anonymoushttp://www.blogger.com/profile/05676993119021367292noreply@blogger.com0tag:blogger.com,1999:blog-2269494441784002778.post-40210170252879097032018-08-23T02:37:00.001-07:002018-08-23T02:40:15.606-07:00PHARMACOEPIDEMIOLOGY 2019<div dir="ltr" style="text-align: left;" trbidi="on">
<h2 class="heading-highlights" style="background: rgb(56, 138, 187); border-radius: 4px 4px 0px 0px; box-shadow: rgba(0, 0, 0, 0.2) 1px 1px 1px; box-sizing: border-box; color: white; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 22px; font-weight: 500; line-height: 1.1; margin: 0px; padding: 5px 45px; position: relative;">
About Conference</h2>
<div>
<br /></div>
<div>
<div>
<b>ME Conferences</b> is delighted and cordially welcomes you to attend the <b>12th International Conference on Pharmacoepidemiology and Clinical Research to be held during March 18-19, 2019</b> <b>in Dubai, UAE</b>. ME Conferences is an open resource platform that conducts 3000+ international events which includes International Conferences, Workshops, Symposia, Trade Shows, Exhibitions and Scientific Conferences in all major disciplines like Clinical, Medical, Pharmaceutical, Engineering, Technology, Business Management and Life Sciences across America, Europe, Middle East, and Asia Pacific. The events are gathering over twenty five million researchers, scholars, students, professionals and industrial personnel throughout the world. World Famous Scientists, Researchers, Academic and business delegates, young scientists and students in their individual fields grace our events as keynote speakers, plenary speakers, poster presenters, and organizing committee members.</div>
<div>
<br /></div>
<div>
<b>Why to Attend???</b></div>
<div>
<br /></div>
<div>
<b>12th International Conference on Pharmacoepidemiology and Clinical Research scheduled during March 18-19, 2019 in Dubai, UAE</b> is organised aiming to bring together leading academic professors, scientists, researchers and students to exchange, share their experiences and research results on all aspects of Pharmacoepidemiology and Clinical research . It also provides a premier interdisciplinary pavement for Pharma, Regulatory, Drug Designing and clinical trial industries to represent their technological innovations and discuss the most recent approaches, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Pharmacoepidemiology & Clinical research.</div>
<div>
<br /></div>
<div>
Pharmaceutical research provides a profitable business opportunity to several pharmaceutical and biotech companies as these technologies have wide application areas such as drug discovery and research followed by New drug delivery systems. Pharmacoepidemiology is the study of the utilization and effects of drugs in large numbers of people; it provides an estimate of the probability of beneficial effects of a drug in a population and the probability of adverse effects. It can be called a bridge science spanning both clinical pharmacology and epidemiologyPart of the task of clinical pharmacology is to provide a risk benefit assessment by effects of drugs in patients:</div>
<div>
<br /></div>
<div>
1. Doing the studies needed to provide an estimate of the probability of beneficial effects on populations,</div>
<div>
<br /></div>
<div>
2. Or assessing the probability of adverse effects on populations.</div>
<div>
<br /></div>
<div>
Pharmacoepidemiology concentrates on clinical patient outcomes from therapeutics by using methods of clinical epidemiology and applying them to understanding the determinants of beneficial and adverse drug effects, effects of genetic variation on drug effect, duration-response relationships, clinical effects of drug-drug interactions, and the effects of medication non-adherence. Pharmacovigilance is a part of pharmacoepidemiology that involves continual monitoring, in a population, for unwanted effects and other safety concerns arising in drugs that are already on the market. Pharmacoepidemiology sometimes also involves the conduct and evaluation of programmatic efforts to improve medication use on a population basis. </div>
<div>
<br /></div>
<div>
Epidemiology is the study of the distribution and determinants of diseases and other health states in populations. Epidemiological studies can be divided into two main types:</div>
<div>
<br /></div>
<div>
1. Descriptive epidemiology describes disease and/or exposure and may consist of calculating rates, e.g., incidence and prevalence. Such descriptive studies do not at this time use health control groups and can only generate hypotheses,but not test them. Studies of drug use would generally fall under descriptive studies.</div>
<div>
<br /></div>
<div>
2. Analytic epidemiology includes two types of studies: observational studies, such as case-control and cohort studies, and experimental studies which include clinical trials or randomized clinical trials. The analytic studies compare an exposed group with a control group and usually designed as hypothesis testing by studies.</div>
<div>
<br /></div>
<div>
Pharmacoepidemiology and Clinical research Congress includes a wide range of Keynote presentations, Oral talks, Poster presentations, Symposia, Workshops, Exhibitions and extensive networking and B2B(Business to Business) interactions.</div>
<div>
<br /></div>
<div>
Mark your dates to meet the experts & join the critical discussions at Pharmacoepidemiology and Clinical Research Congress scheduled during March 18-19, 2019 in Dubai, UAE. Register now to unleash Advanced Clinical research and compliance in the arena of Pharmacoepidemiology.</div>
<div>
<br /></div>
<div>
<b>Who Should Attend??</b></div>
<div>
<br /></div>
<div>
Directors,Senior Directors,Executive Directors and Vice Presidents and Senior Vice Presidents, Executive Vice Presidents and Heads/Leaders/Partners of:</div>
<div>
<br /></div>
<div>
<br />
<ul style="text-align: left;">
<li>CROs and CMOs</li>
<li>Clinical Research Sites</li>
<li>Pharma/Biotech and Medical Device industries</li>
<li>Hospitals, Associations</li>
<li>Medical Advisors</li>
<li>Medical Directors, Principal Investigators, Methodologists, and other clinical research professionals along with Academicians. University Faculties like Directors, Senior Professors and Assistant Professors and Associate Professor, Research Scholars, Adepts scientists who are related to clinical and medical research.</li>
</ul>
</div>
<div>
<br /></div>
<div>
<b>Clinical and Pharmaceutical and biotech industry professionals with responsibilities in:</b></div>
<div>
<br /></div>
<div>
<ul style="text-align: left;">
<li>Clinical Research & Development </li>
<li>Clinical Design/ Protocol Design/ Clinical Strategy</li>
<li>Global Clinical Operations</li>
<li>Clinical Outsourcing </li>
<li>Biostatistics/Data management</li>
<li>Patient Recruitment/Enrollment </li>
<li>Clinical Trial Management</li>
<li>Clinical Trial Supplies</li>
<li>Regulatory Affairs</li>
</ul>
<div>
<div style="background-color: white;">
<h2 class="heading-highlights" style="background: rgb(56, 138, 187); border-radius: 4px 4px 0px 0px; box-shadow: rgba(0, 0, 0, 0.2) 1px 1px 1px; box-sizing: border-box; color: white; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 22px; font-weight: 500; line-height: 1.1; margin: 0px; padding: 5px 45px; position: relative;">
Conference Highlights</h2>
<div style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<br /></div>
<div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
</div>
<ul style="text-align: left;">
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/molecular-pharmacoepidemiology" title="MOLECULAR PHARMACOEPIDEMIOLOGY">MOLECULAR PHARMACOEPIDEMIOLOGY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/clinical-pharmacology-and-therapeutics" title="CLINICAL PHARMACOLOGY and THERAPEUTICS ">CLINICAL
PHARMACOLOGY and THERAPEUTICS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/pharmacogenetics-and-pharmacogenomics" title="PHARMACOGENETICS and PHARMACOGENOMICS ">PHARMACOGENETICS and
PHARMACOGENOMICS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/neuropharmacology-and-psychotropic-medicine" title="NEUROPHARMACOLOGY and PSYCHOTROPIC MEDICINE ">NEUROPHARMACOLOGY and
PSYCHOTROPIC MEDICINE</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/cardiovascular-pharmacology" title="CARDIOVASCULAR PHARMACOLOGY ">CARDIOVASCULAR PHARMACOLOGY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/nursing-and-anesthesia-pharmacology" title="NURSING and ANESTHESIA PHARMACOLOGY">NURSING and ANESTHESIA PHARMACOLOGY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/immunopharmacology" title="IMMUNOPHARMACOLOGY ">IMMUNOPHARMACOLOGY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/toxicology-toxicogenomic-studies" title="TOXICOLOGY & TOXICOGENOMIC STUDIES ">TOXICOLOGY &
TOXICOGENOMIC STUDIES</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/cancer-pharmacoepidemiology-and-genomics" title="CANCER PHARMACOEPIDEMIOLOGY and GENOMICS">CANCER PHARMACOEPIDEMIOLOGY
and GENOMICS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/cholinergic-drugs" title="CHOLINERGIC DRUGS">CHOLINERGIC DRUGS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/antibiotic-pharmacology" title="ANTIBIOTIC PHARMACOLOGY">ANTIBIOTIC PHARMACOLOGY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/rare-diseases-drug-development" title="RARE DISEASES & DRUG DEVELOPMENT">RARE DISEASES & DRUG
DEVELOPMENT</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/personalized-precision-medicine" title="PERSONALIZED & PRECISION MEDICINE">PERSONALIZED & PRECISION
MEDICINE</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/drugs-in-pregnancy-lactation" title="DRUGS IN PREGNANCY & LACTATION">DRUGS IN PREGNANCY & LACTATION</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/renal-pharmacoepidemiology-adrenergic-drugs" title="RENAL PHARMACOEPIDEMIOLOGY & ADRENERGIC DRUGS">RENAL
PHARMACOEPIDEMIOLOGY & ADRENERGIC DRUGS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/oral-bisphosphonates-osteoporosis" title="ORAL BISPHOSPHONATES & OSTEOPOROSIS">ORAL BISPHOSPHONATES &
OSTEOPOROSIS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/pharmacoepidemiology-in-health-care-and-industry" title="PHARMACOEPIDEMIOLOGY in HEALTH-CARE and INDUSTRY">PHARMACOEPIDEMIOLOGY
in HEALTH-CARE and INDUSTRY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/clinical-and-industrial-pharmacy" title="CLINICAL and INDUSTRIAL PHARMACY">CLINICAL and INDUSTRIAL PHARMACY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/regulatory-affairs-drug-safety-utilization-research" title="REGULATORY AFFAIRS, DRUG SAFETY & UTILIZATION RESEARCH">REGULATORY
AFFAIRS, DRUG SAFETY & UTILIZATION RESEARCH</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/patient-safety-and-adverse-drug-reactions" title="PATIENT SAFETY and ADVERSE DRUG REACTIONS ">PATIENT SAFETY and ADVERSE
DRUG REACTIONS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/innovations-in-clinical-trials" title="INNOVATIONS in CLINICAL TRIALS">INNOVATIONS in CLINICAL TRIALS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/clinical-data-management" title="CLINICAL DATA MANAGEMENT ">CLINICAL DATA MANAGEMENT</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/pharmacokinetics-and-pharmacodynamics" title="PHARMACOKINETICS and PHARMACODYNAMICS">PHARMACOKINETICS and
PHARMACODYNAMICS</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/advances-in-pharmacological-research" title="ADVANCES in PHARMACOLOGICAL RESEARCH ">ADVANCES in PHARMACOLOGICAL
RESEARCH</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/nanotechnology-in-drug-delivery" title="NANOTECHNOLOGY in DRUG DELIVERY">NANOTECHNOLOGY in DRUG DELIVERY</a></li>
<li><a href="https://pharmacoepidemiology.pharmaceuticalconferences.com/events-list/drug-discovery-and-drug-screening" title="DRUG DISCOVERY and DRUG SCREENING">DRUG DISCOVERY and DRUG SCREENING</a> </li>
</ul>
<br />
<div style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<h2 class="heading-highlights" style="background: rgb(56, 138, 187); border-radius: 4px 4px 0px 0px; box-shadow: rgba(0, 0, 0, 0.2) 1px 1px 1px; box-sizing: border-box; color: white; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 22px; font-weight: 500; line-height: 1.1; margin: 0px; padding: 5px 45px; position: relative;">
Special Issues</h2>
<div>
<br /></div>
</div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div>
<ul style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px; line-height: 1.4; margin: 0.5em 0px; padding: 0px 2.5em; text-align: justify;">
<li style="margin: 0px 0px 0.25em; padding: 0px;"><span style="text-align: left;"> All accepted abstracts will be published in respective Supported International Journals.</span></li>
<li style="margin: 0px 0px 0.25em; padding: 0px;"><span style="text-align: left;"> Abstracts will be provided with Digital Object Identifier by Cross Ref.</span></li>
</ul>
<br style="text-align: justify;" /><div style="text-align: left;">
<b style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px; text-align: justify;">See more at: </b><span style="color: #0000ee; font-family: arial, tahoma, helvetica, freesans, sans-serif;"><span style="font-size: 13.2px;"><b><u>https://pharmacoepidemiology.pharmaceuticalconferences.com/</u></b></span></span></div>
</div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div class="MsoNormal" style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<br /></div>
</div>
<div style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<br /></div>
</div>
</div>
</div>
</div>
</div>
Asia Pacific Conferencehttp://www.blogger.com/profile/10138955357050690328noreply@blogger.com0